PARD6B

Across TCGA pan-cancer cohorts, PARD6B mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of PARD6B’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where PARD6B mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types PARD6B is over-expressed in tumor, although a few such as CCRCC and LUAD show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where PARD6B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PARD6B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	II,III,IV	−0.259	<.001	11	view →
LUAD	Male	III,IV	−0.658	<.001	9	view →
LSCC	Female	All	−1.316	<.001	8	view →
PDAC	Male	II,III,IV	+0.675	<.001	8	view →
HNSC	Male	All	−0.305	<.001	4	view →
OV	All	All	+0.599	.009	2	view →
COAD	All	All	+0.186	.028	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

PARD6B–CCRCC

Open the CCRCC breakdown →